Fuisz Pharma has a US patent pending on a system for monitoring drug compliance
Fuisz Pharma has announced the publication of a US patent application for a system to confirm compliant use of medication.
The patent application, US20110182827 (Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent), is directed towards a substance that is visible in normal or special light, which leaves a temporary stain in the patient's buccal or vaginal cavity. This stain can then be assessed by medical personnel to ascertain medication levels and, therefore, to determine compliance.
"This patent application sets forth a highly effective method of confirming compliant use of medications for the buccal or vaginal cavities," said Joseph Matus Fuisz, managing member of Fuisz Pharma. "Its disclosure and claims are highly complimentary to the Gruber patent previously acquired by Fuisz Pharma (US 7,214,385 Pharmaceutical Formulation Containing Dye), which covers the use of a dye to show the misuse of an opioid dosage form, such as by snorting."
Lack of compliance is a significant issue for pharma companies. According to a Capgemini report, up to 50 per cent of patients with chronic conditions (such as HIV or arthritis) are not compliant with their required treatment regimes. Non-adherence results in annual costs of close to €125bn in the EU and $300bn in the US.
In the past, using electronic recorders has been shown to increase patient compliance threefold. Monitoring patients' medication usage electronically – for example, by using pill bottles with a Medication Events Monitoring Systems (MEMS) lid – and potentially also offering a prompt if the frequency falls below a particular level, is still the most popular method of increasing compliance. However, these methods simply monitor either patients' self-reported compliance, or the frequency of (for example) pill bottle opening (as opposed to monitoring how much medication patients actually take), rather than assessing compliance through the levels of medication present in the patient's body.
Fuisz Pharma, a family-held private pharmaceutical company based in Miami, Florida (US), operates in various drug delivery systems, anti-opiate-abuse technology, food systems, specialised women's health, tobacco harm reduction, and web based systems, as well as novel video based marketing systems. The company primarily originates patent pending systems, which it then licenses or sells.